ID   IRAK1_HUMAN             Reviewed;         712 AA.
AC   P51617; D3DWW3; D3DWW4; Q7Z5V4; Q96C06; Q96RL2;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   10-MAY-2017, entry version 181.
DE   RecName: Full=Interleukin-1 receptor-associated kinase 1;
DE            Short=IRAK-1;
DE            EC=2.7.11.1;
GN   Name=IRAK1; Synonyms=IRAK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND
RP   VARIANTS SER-196 AND LEU-532.
RX   PubMed=8599092; DOI=10.1126/science.271.5252.1128;
RA   Cao Z., Henzel W.J., Gao X.;
RT   "IRAK: a kinase associated with the interleukin-1 receptor.";
RL   Science 271:1128-1131(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=10723722; DOI=10.1007/s003350010035;
RA   Reichwald K., Thiesen J., Wiehe T., Weitzel J., Poustka W.A.,
RA   Rosenthal A., Platzer M., Stratling W.H., Kioschis P.;
RT   "Comparative sequence analysis of the MECP2-locus in human and mouse
RT   reveals new transcribed regions.";
RL   Mamm. Genome 11:182-190(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, TISSUE SPECIFICITY,
RP   AND PHOSPHORYLATION.
RX   PubMed=11397809; DOI=10.1074/jbc.M103815200;
RA   Jensen L.E., Whitehead A.S.;
RT   "IRAK1b, a novel alternative splice variant of interleukin-1 receptor-
RT   associated kinase (IRAK), mediates interleukin-1 signaling and has
RT   prolonged stability.";
RL   J. Biol. Chem. 276:29037-29044(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RX   PubMed=16024789; DOI=10.1128/MCB.25.15.6521-6532.2005;
RA   Rao N., Nguyen S., Ngo K., Fung-Leung W.P.;
RT   "A novel splice variant of interleukin-1 receptor (IL-1R)-associated
RT   kinase 1 plays a negative regulatory role in Toll/IL-1R-induced
RT   inflammatory signaling.";
RL   Mol. Cell. Biol. 25:6521-6532(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH MYD88.
RX   PubMed=9430229; DOI=10.1016/S1074-7613(00)80402-1;
RA   Wesche H., Henzel W.J., Shillinglaw W., Li S., Cao Z.;
RT   "MyD88: an adapter that recruits IRAK to the IL-1 receptor complex.";
RL   Immunity 7:837-847(1997).
RN   [9]
RP   INTERACTION WITH TOLLIP.
RX   PubMed=10854325; DOI=10.1038/35014038;
RA   Burns K., Clatworthy J., Martin L., Martinon F., Plumpton C.,
RA   Maschera B., Lewis A., Ray K., Tschopp J., Volpe F.;
RT   "Tollip, a new component of the IL-1R1 pathway, links IRAK to the IL-1
RT   receptor.";
RL   Nat. Cell Biol. 2:346-351(2000).
RN   [10]
RP   INTERACTION WITH IRAK4.
RX   PubMed=11960013; DOI=10.1073/pnas.082100399;
RA   Li S., Strelow A., Fontana E.J., Wesche H.;
RT   "IRAK4: a novel member of the IRAK family with the properties of an
RT   IRAK-kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:5567-5572(2002).
RN   [11]
RP   INTERACTION WITH PELI1 AND TRAF6.
RX   PubMed=12496252; DOI=10.1074/jbc.M212112200;
RA   Jiang Z., Johnson H.J., Nie H., Qin J., Bird T.A., Li X.;
RT   "Pellino 1 is required for interleukin-1 (IL-1)-mediated signaling
RT   through its interaction with the IL-1 receptor-associated kinase 4
RT   (IRAK4)-IRAK-tumor necrosis factor receptor-associated factor 6
RT   (TRAF6) complex.";
RL   J. Biol. Chem. 278:10952-10956(2003).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF PELI2.
RX   PubMed=12860405; DOI=10.1016/S0014-5793(03)00697-5;
RA   Strelow A., Kollewe C., Wesche H.;
RT   "Characterization of Pellino2, a substrate of IRAK1 and IRAK4.";
RL   FEBS Lett. 547:157-161(2003).
RN   [13]
RP   PHOSPHORYLATION BY IRAK4.
RX   PubMed=12538665; DOI=10.1084/jem.20021790;
RA   Burns K., Janssens S., Brissoni B., Olivos N., Beyaert R., Tschopp J.;
RT   "Inhibition of interleukin 1 receptor/Toll-like receptor signaling
RT   through the alternatively spliced, short form of MyD88 is due to its
RT   failure to recruit IRAK-4.";
RL   J. Exp. Med. 197:263-268(2003).
RN   [14]
RP   INTERACTION WITH PELI3.
RX   PubMed=12874243; DOI=10.4049/jimmunol.171.3.1500;
RA   Jensen L.E., Whitehead A.S.;
RT   "Pellino3, a novel member of the Pellino protein family, promotes
RT   activation of c-Jun and Elk-1 and may act as a scaffolding protein.";
RL   J. Immunol. 171:1500-1506(2003).
RN   [15]
RP   FUNCTION, AND PHOSPHORYLATION AT THR-66.
RX   PubMed=14684752; DOI=10.1074/jbc.C300431200;
RA   Mamidipudi V., Lin C., Seibenhener M.L., Wooten M.W.;
RT   "Regulation of interleukin receptor-associated kinase (IRAK)
RT   phosphorylation and signaling by iota protein kinase C.";
RL   J. Biol. Chem. 279:4161-4165(2004).
RN   [16]
RP   PHOSPHORYLATION AT THR-209 AND THR-387, DOMAIN, AND MUTAGENESIS OF
RP   THR-209 AND THR-387.
RX   PubMed=14625308; DOI=10.1074/jbc.M309251200;
RA   Kollewe C., Mackensen A.C., Neumann D., Knop J., Cao P., Li S.,
RA   Wesche H., Martin M.U.;
RT   "Sequential autophosphorylation steps in the interleukin-1 receptor-
RT   associated kinase-1 regulate its availability as an adapter in
RT   interleukin-1 signaling.";
RL   J. Biol. Chem. 279:5227-5236(2004).
RN   [17]
RP   FUNCTION, AND MUTAGENESIS OF LYS-239.
RX   PubMed=15084582; DOI=10.1074/jbc.M400785200;
RA   Qin J., Jiang Z., Qian Y., Casanova J.-L., Li X.;
RT   "IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-
RT   associated kinase phosphorylation and IL-1 responsiveness.";
RL   J. Biol. Chem. 279:26748-26753(2004).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF STAT3.
RX   PubMed=15465816; DOI=10.1074/jbc.M410369200;
RA   Huang Y., Li T., Sane D.C., Li L.;
RT   "IRAK1 serves as a novel regulator essential for lipopolysaccharide-
RT   induced interleukin-10 gene expression.";
RL   J. Biol. Chem. 279:51697-51703(2004).
RN   [19]
RP   INTERACTION WITH IL1RL1.
RX   PubMed=16286016; DOI=10.1016/j.immuni.2005.09.015;
RA   Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K.,
RA   Zurawski G., Moshrefi M., Qin J., Li X., Gorman D.M., Bazan J.F.,
RA   Kastelein R.A.;
RT   "IL-33, an interleukin-1-like cytokine that signals via the IL-1
RT   receptor-related protein ST 2 and induces T helper type 2-associated
RT   cytokines.";
RL   Immunity 23:479-490(2005).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF IRF7.
RX   PubMed=15767370; DOI=10.1084/jem.20042372;
RA   Uematsu S., Sato S., Yamamoto M., Hirotani T., Kato H., Takeshita F.,
RA   Matsuda M., Coban C., Ishii K.J., Kawai T., Takeuchi O., Akira S.;
RT   "Interleukin-1 receptor-associated kinase-1 plays an essential role
RT   for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha}
RT   induction.";
RL   J. Exp. Med. 201:915-923(2005).
RN   [21]
RP   IDENTIFICATION IN COMPLEX WITH IRAK4; MYD88; PELI1 AND TRAF6.
RX   PubMed=16951688; DOI=10.1038/ni1383;
RA   Choi K.C., Lee Y.S., Lim S., Choi H.K., Lee C.H., Lee E.K., Hong S.,
RA   Kim I.H., Kim S.J., Park S.H.;
RT   "Smad6 negatively regulates interleukin 1-receptor-Toll-like receptor
RT   signaling through direct interaction with the adaptor Pellino-1.";
RL   Nat. Immunol. 7:1057-1065(2006).
RN   [22]
RP   SUMOYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=16690127; DOI=10.1016/j.molimm.2006.03.021;
RA   Su J., Richter K., Zhang C., Gu Q., Li L.;
RT   "Differential regulation of interleukin-1 receptor associated kinase 1
RT   (IRAK1) splice variants.";
RL   Mol. Immunol. 44:900-905(2007).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF PELI1.
RX   PubMed=17997719; DOI=10.1042/BJ20071365;
RA   Ordureau A., Smith H., Windheim M., Peggie M., Carrick E., Morrice N.,
RA   Cohen P.;
RT   "The IRAK-catalysed activation of the E3 ligase function of Pellino
RT   isoforms induces the Lys63-linked polyubiquitination of IRAK1.";
RL   Biochem. J. 409:43-52(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-131, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [25]
RP   UBIQUITINATION AT LYS-134 AND LYS-180 BY TRAF6, AND INTERACTION WITH
RP   IKBKG/NEMO.
RX   PubMed=18347055; DOI=10.1128/MCB.02098-07;
RA   Conze D.B., Wu C.J., Thomas J.A., Landstrom A., Ashwell J.D.;
RT   "Lys63-linked polyubiquitination of IRAK-1 is required for
RT   interleukin-1 receptor- and toll-like receptor-mediated NF-kappaB
RT   activation.";
RL   Mol. Cell. Biol. 28:3538-3547(2008).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [27]
RP   UBIQUITINATION.
RX   PubMed=19675569; DOI=10.1038/nature08247;
RA   Xia Z.-P., Sun L., Chen X., Pineda G., Jiang X., Adhikari A., Zeng W.,
RA   Chen Z.J.;
RT   "Direct activation of protein kinases by unanchored polyubiquitin
RT   chains.";
RL   Nature 461:114-119(2009).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF TIRAP.
RX   PubMed=20400509; DOI=10.1074/jbc.M109.098137;
RA   Dunne A., Carpenter S., Brikos C., Gray P., Strelow A., Wesche H.,
RA   Morrice N., O'Neill L.A.;
RT   "IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and
RT   degradation of MyD88 adaptor-like (Mal).";
RL   J. Biol. Chem. 285:18276-18282(2010).
RN   [29]
RP   REVIEW ON FUNCTION.
RX   PubMed=17890055; DOI=10.1016/j.cellsig.2007.08.009;
RA   Gottipati S., Rao N.L., Fung-Leung W.P.;
RT   "IRAK1: a critical signaling mediator of innate immunity.";
RL   Cell. Signal. 20:269-276(2008).
RN   [30]
RP   REVIEW ON FUNCTION.
RX   PubMed=19022706; DOI=10.1016/j.it.2008.10.001;
RA   Moynagh P.N.;
RT   "The Pellino family: IRAK E3 ligases with emerging roles in innate
RT   immune signalling.";
RL   Trends Immunol. 30:33-42(2009).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-371; SER-375 AND
RP   SER-556, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-398; MET-412; HIS-421; LEU-532;
RP   SER-619; MET-625; TRP-638 AND GLY-690.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that plays a critical
CC       role in initiating innate immune response against foreign
CC       pathogens. Involved in Toll-like receptor (TLR) and IL-1R
CC       signaling pathways. Is rapidly recruited by MYD88 to the receptor-
CC       signaling complex upon TLR activation. Association with MYD88
CC       leads to IRAK1 phosphorylation by IRAK4 and subsequent
CC       autophosphorylation and kinase activation. Phosphorylates E3
CC       ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to
CC       promote pellino-mediated polyubiquitination of IRAK1. Then, the
CC       ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated
CC       IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and
CC       the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs
CC       (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear
CC       translocation and activation. Alternatively, phosphorylates TIRAP
CC       to promote its ubiquitination and subsequent degradation.
CC       Phosphorylates the interferon regulatory factor 7 (IRF7) to induce
CC       its activation and translocation to the nucleus, resulting in
CC       transcriptional activation of type I IFN genes, which drive the
CC       cell in an antiviral state. When sumoylated, translocates to the
CC       nucleus and phosphorylates STAT3. {ECO:0000269|PubMed:11397809,
CC       ECO:0000269|PubMed:12860405, ECO:0000269|PubMed:14684752,
CC       ECO:0000269|PubMed:15084582, ECO:0000269|PubMed:15465816,
CC       ECO:0000269|PubMed:15767370, ECO:0000269|PubMed:17997719,
CC       ECO:0000269|PubMed:20400509}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- SUBUNIT: Homodimer (By similarity). Forms a complex with TRAF6,
CC       PELI1, IRAK4 and MYD88 (PubMed:16951688). Direct binding of SMAD6
CC       to PELI1 prevents complex formation and hence negatively regulates
CC       IL1R-TLR signaling and eventually NF-kappa-B-mediated gene
CC       expression (PubMed:16951688). The TRAF6-PELI1-IRAK4-MYD88 complex
CC       recruits MAP3K7/TAK1, TAB1 and TAB2 to mediate NF-kappa-B
CC       activation (PubMed:16951688). Interaction with MYD88 recruits
CC       IRAK1 to the stimulated receptor complex (PubMed:9430229).
CC       Interacts with TOLLIP; this interaction occurs in the cytosol
CC       prior to receptor activation (PubMed:10854325). Interacts with
CC       IL1RL1 (PubMed:16286016). Interacts with PELI1 and TRAF6
CC       (PubMed:12496252). Interacts (when polyubiquitinated) with
CC       IKBKG/NEMO (PubMed:18347055). Interacts with RSAD2/viperin (By
CC       similarity). Interacts with IRAK1BP1 (By similarity). Interacts
CC       with PELI2 (By similarity). Interacts with ZC3H12A; this
CC       interaction increases the interaction between ZC3H12A and
CC       IKBKB/IKKB (By similarity). Interacts with IRAK4
CC       (PubMed:11960013). Interacts with PELI3 (PubMed:12874243).
CC       {ECO:0000250|UniProtKB:Q62406, ECO:0000269|PubMed:10854325,
CC       ECO:0000269|PubMed:11960013, ECO:0000269|PubMed:12496252,
CC       ECO:0000269|PubMed:12874243, ECO:0000269|PubMed:16286016,
CC       ECO:0000269|PubMed:16951688, ECO:0000269|PubMed:18347055,
CC       ECO:0000269|PubMed:9430229}.
CC   -!- INTERACTION:
CC       Q15306:IRF4; NbExp=2; IntAct=EBI-358664, EBI-751345;
CC       Q92985:IRF7; NbExp=2; IntAct=EBI-358664, EBI-968267;
CC       Q99836:MYD88; NbExp=2; IntAct=EBI-358664, EBI-447677;
CC       Q96FA3:PELI1; NbExp=3; IntAct=EBI-358664, EBI-448369;
CC       Q9HAT8:PELI2; NbExp=3; IntAct=EBI-358664, EBI-448407;
CC       Q13526:PIN1; NbExp=10; IntAct=EBI-358664, EBI-714158;
CC       P58753:TIRAP; NbExp=2; IntAct=EBI-358664, EBI-528644;
CC       Q86WV6:TMEM173; NbExp=2; IntAct=EBI-358664, EBI-2800345;
CC       Q9Y4K3:TRAF6; NbExp=2; IntAct=EBI-358664, EBI-359276;
CC       Q8VCW4:Unc93b1 (xeno); NbExp=2; IntAct=EBI-358664, EBI-6116986;
CC       Q5D1E7:Zc3h12a (xeno); NbExp=3; IntAct=EBI-358664, EBI-5326026;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16690127}.
CC       Nucleus {ECO:0000269|PubMed:16690127}. Lipid droplet
CC       {ECO:0000250}. Note=Translocates to the nucleus when sumoylated.
CC       RSAD2/viperin recruits it to the lipid droplet (By similarity).
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=a;
CC         IsoId=P51617-1; Sequence=Displayed;
CC       Name=2; Synonyms=b;
CC         IsoId=P51617-2; Sequence=VSP_011851;
CC         Note=Inactive.;
CC       Name=3;
CC         IsoId=P51617-3; Sequence=VSP_011849, VSP_011850, VSP_011851;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=P51617-4; Sequence=VSP_041950;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are ubiquitously
CC       expressed in all tissues examined, with isoform 1 being more
CC       strongly expressed than isoform 2. {ECO:0000269|PubMed:11397809}.
CC   -!- DOMAIN: The ProST region is composed of many proline and serine
CC       residues (more than 20 of each) and some threonines. This region
CC       is the site of IRAK-1 hyperphosphorylation.
CC       {ECO:0000269|PubMed:14625308}.
CC   -!- PTM: Following recruitment on the activated receptor complex,
CC       phosphorylated on Thr-209, probably by IRAK4, resulting in a
CC       conformational change of the kinase domain, allowing further
CC       phosphorylations to take place. Thr-387 phosphorylation in the
CC       activation loop is required to achieve full enzymatic activity.
CC       {ECO:0000269|PubMed:11397809, ECO:0000269|PubMed:12538665,
CC       ECO:0000269|PubMed:14625308, ECO:0000269|PubMed:14684752}.
CC   -!- PTM: Polyubiquitinated by TRAF6 after cell stimulation with IL-1-
CC       beta by PELI1, PELI2 and PELI3. Polyubiquitination occurs with
CC       polyubiquitin chains linked through 'Lys-63'. Ubiquitination
CC       promotes interaction with NEMO/IKBKG. Also sumoylated; leading to
CC       nuclear translocation. {ECO:0000269|PubMed:16690127,
CC       ECO:0000269|PubMed:18347055, ECO:0000269|PubMed:19675569}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. Pelle subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L76191; AAC41949.1; -; mRNA.
DR   EMBL; AF030876; AAC08756.1; -; Genomic_DNA.
DR   EMBL; AF346607; AAK62888.1; -; mRNA.
DR   EMBL; DQ054788; AAY88246.1; -; mRNA.
DR   EMBL; U52112; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471172; EAW72762.1; -; Genomic_DNA.
DR   EMBL; CH471172; EAW72763.1; -; Genomic_DNA.
DR   EMBL; CH471172; EAW72764.1; -; Genomic_DNA.
DR   EMBL; CH471172; EAW72765.1; -; Genomic_DNA.
DR   EMBL; BC054000; AAH54000.1; -; mRNA.
DR   EMBL; BC014963; AAH14963.1; -; mRNA.
DR   CCDS; CCDS14740.1; -. [P51617-1]
DR   CCDS; CCDS35443.1; -. [P51617-4]
DR   CCDS; CCDS35444.1; -. [P51617-2]
DR   PIR; G02512; G02512.
DR   RefSeq; NP_001020413.1; NM_001025242.1. [P51617-2]
DR   RefSeq; NP_001020414.1; NM_001025243.1. [P51617-4]
DR   RefSeq; NP_001560.2; NM_001569.3. [P51617-1]
DR   UniGene; Hs.522819; -.
DR   ProteinModelPortal; P51617; -.
DR   BioGrid; 109863; 120.
DR   DIP; DIP-397N; -.
DR   IntAct; P51617; 72.
DR   MINT; MINT-97088; -.
DR   STRING; 9606.ENSP00000358997; -.
DR   BindingDB; P51617; -.
DR   ChEMBL; CHEMBL3357; -.
DR   GuidetoPHARMACOLOGY; 2042; -.
DR   iPTMnet; P51617; -.
DR   PhosphoSitePlus; P51617; -.
DR   BioMuta; IRAK1; -.
DR   DMDM; 8928535; -.
DR   EPD; P51617; -.
DR   MaxQB; P51617; -.
DR   PaxDb; P51617; -.
DR   PeptideAtlas; P51617; -.
DR   PRIDE; P51617; -.
DR   DNASU; 3654; -.
DR   Ensembl; ENST00000369974; ENSP00000358991; ENSG00000184216. [P51617-4]
DR   Ensembl; ENST00000369980; ENSP00000358997; ENSG00000184216. [P51617-1]
DR   Ensembl; ENST00000393687; ENSP00000377291; ENSG00000184216. [P51617-2]
DR   GeneID; 3654; -.
DR   KEGG; hsa:3654; -.
DR   UCSC; uc004fjr.2; human. [P51617-1]
DR   CTD; 3654; -.
DR   DisGeNET; 3654; -.
DR   GeneCards; IRAK1; -.
DR   GeneCards; MIR718; -.
DR   H-InvDB; HIX0017146; -.
DR   HGNC; HGNC:6112; IRAK1.
DR   HPA; CAB004461; -.
DR   HPA; HPA054476; -.
DR   MalaCards; IRAK1; -.
DR   MIM; 300283; gene.
DR   neXtProt; NX_P51617; -.
DR   OpenTargets; ENSG00000184216; -.
DR   Orphanet; 93552; Pediatric systemic lupus erythematosus.
DR   Orphanet; 536; Systemic lupus erythematosus.
DR   PharmGKB; PA29912; -.
DR   eggNOG; KOG1187; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00530000063073; -.
DR   HOGENOM; HOG000015226; -.
DR   HOVERGEN; HBG052144; -.
DR   InParanoid; P51617; -.
DR   KO; K04730; -.
DR   OMA; AVMRNTV; -.
DR   OrthoDB; EOG091G0YKT; -.
DR   PhylomeDB; P51617; -.
DR   TreeFam; TF328924; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-166058; MyD88:Mal cascade initiated on plasma membrane.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-209543; p75NTR recruits signalling complexes.
DR   Reactome; R-HSA-209560; NF-kB is activated and signals survival.
DR   Reactome; R-HSA-445989; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; R-HSA-446652; Interleukin-1 signaling.
DR   Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-937039; IRAK1 recruits IKK complex.
DR   Reactome; R-HSA-975110; TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling.
DR   Reactome; R-HSA-975138; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation.
DR   Reactome; R-HSA-975144; IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation.
DR   Reactome; R-HSA-975155; MyD88 dependent cascade initiated on endosome.
DR   Reactome; R-HSA-975871; MyD88 cascade initiated on plasma membrane.
DR   SignaLink; P51617; -.
DR   SIGNOR; P51617; -.
DR   GeneWiki; IRAK1; -.
DR   GenomeRNAi; 3654; -.
DR   PRO; PR:P51617; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000184216; -.
DR   CleanEx; HS_IRAK1; -.
DR   ExpressionAtlas; P51617; baseline and differential.
DR   Genevisible; P51617; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0045323; C:interleukin-1 receptor complex; NAS:UniProtKB.
DR   GO; GO:0005811; C:lipid particle; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0031072; F:heat shock protein binding; IEA:Ensembl.
DR   GO; GO:0016301; F:kinase activity; IDA:MGI.
DR   GO; GO:0004704; F:NF-kappaB-inducing kinase activity; TAS:ProtInc.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:Reactome.
DR   GO; GO:0007250; P:activation of NF-kappaB-inducing kinase activity; IDA:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0007254; P:JNK cascade; TAS:Reactome.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0070423; P:nucleotide-binding oligomerization domain containing signaling pathway; TAS:Reactome.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IMP:MGI.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IBA:GO_Central.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0051259; P:protein oligomerization; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0001959; P:regulation of cytokine-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IMP:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0034134; P:toll-like receptor 2 signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IBA:GO_Central.
DR   GO; GO:0034162; P:toll-like receptor 9 signaling pathway; TAS:Reactome.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007178; P:transmembrane receptor protein serine/threonine kinase signaling pathway; NAS:UniProtKB.
DR   GO; GO:0060337; P:type I interferon signaling pathway; IMP:BHF-UCL.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Immunity; Innate immunity; Isopeptide bond;
KW   Kinase; Lipid droplet; Magnesium; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN         1    712       Interleukin-1 receptor-associated kinase
FT                                1.
FT                                /FTId=PRO_0000086030.
FT   DOMAIN       27    106       Death.
FT   DOMAIN      212    521       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     218    226       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     342    345       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      110    211       ProST region.
FT   COMPBIAS    649    655       Poly-Ser.
FT   COMPBIAS    688    691       Poly-Ser.
FT   ACT_SITE    340    340       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     239    239       ATP.
FT   BINDING     358    358       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      66     66       Phosphothreonine; by PKC/PRKCI.
FT                                {ECO:0000269|PubMed:14684752}.
FT   MOD_RES     131    131       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     209    209       Phosphothreonine; by IRAK4.
FT                                {ECO:0000305|PubMed:14625308}.
FT   MOD_RES     371    371       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     375    375       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     387    387       Phosphothreonine.
FT                                {ECO:0000269|PubMed:14625308}.
FT   MOD_RES     556    556       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK    134    134       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:18347055}.
FT   CROSSLNK    180    180       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:18347055}.
FT   VAR_SEQ      45     45       F -> FGGWRRAAGGREARGLLAPTPDAPRPA (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_011849.
FT   VAR_SEQ     435    513       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:16024789}.
FT                                /FTId=VSP_041950.
FT   VAR_SEQ     478    492       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_011850.
FT   VAR_SEQ     513    542       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:11397809,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_011851.
FT   VARIANT     194    194       R -> H (in dbSNP:rs11465830).
FT                                /FTId=VAR_051629.
FT   VARIANT     196    196       F -> S (in dbSNP:rs1059702).
FT                                {ECO:0000269|PubMed:8599092}.
FT                                /FTId=VAR_051630.
FT   VARIANT     203    203       C -> S (in dbSNP:rs10127175).
FT                                /FTId=VAR_051631.
FT   VARIANT     398    398       T -> M (in dbSNP:rs56340948).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040573.
FT   VARIANT     412    412       V -> M (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040574.
FT   VARIANT     421    421       Q -> H (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040575.
FT   VARIANT     532    532       S -> L (in dbSNP:rs1059703).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8599092}.
FT                                /FTId=VAR_040576.
FT   VARIANT     619    619       G -> S (in dbSNP:rs34112487).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040577.
FT   VARIANT     625    625       T -> M (in dbSNP:rs35638718).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040578.
FT   VARIANT     638    638       R -> W (in dbSNP:rs56082801).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040579.
FT   VARIANT     690    690       S -> G (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040580.
FT   MUTAGEN     209    209       T->A: Completely abolishes auto-
FT                                phosphorylation in the kinase domain.
FT                                {ECO:0000269|PubMed:14625308}.
FT   MUTAGEN     239    239       K->S: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15084582}.
FT   MUTAGEN     387    387       T->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:14625308}.
SQ   SEQUENCE   712 AA;  76537 MW;  A7ADED75D3A3981D CRC64;
     MAGGPGPGEP AAPGAQHFLY EVPPWVMCRF YKVMDALEPA DWCQFAALIV RDQTELRLCE
     RSGQRTASVL WPWINRNARV ADLVHILTHL QLLRARDIIT AWHPPAPLPS PGTTAPRPSS
     IPAPAEAEAW SPRKLPSSAS TFLSPAFPGS QTHSGPELGL VPSPASLWPP PPSPAPSSTK
     PGPESSVSLL QGARPFPFCW PLCEISRGTH NFSEELKIGE GGFGCVYRAV MRNTVYAVKR
     LKENADLEWT AVKQSFLTEV EQLSRFRHPN IVDFAGYCAQ NGFYCLVYGF LPNGSLEDRL
     HCQTQACPPL SWPQRLDILL GTARAIQFLH QDSPSLIHGD IKSSNVLLDE RLTPKLGDFG
     LARFSRFAGS SPSQSSMVAR TQTVRGTLAY LPEEYIKTGR LAVDTDTFSF GVVVLETLAG
     QRAVKTHGAR TKYLKDLVEE EAEEAGVALR STQSTLQAGL AADAWAAPIA MQIYKKHLDP
     RPGPCPPELG LGLGQLACCC LHRRAKRRPP MTQVYERLEK LQAVVAGVPG HSEAASCIPP
     SPQENSYVSS TGRAHSGAAP WQPLAAPSGA SAQAAEQLQR GPNQPVESDE SLGGLSAALR
     SWHLTPSCPL DPAPLREAGC PQGDTAGESS WGSGPGSRPT AVEGLALGSS ASSSSEPPQI
     IINPARQKMV QKLALYEDGA LDSLQLLSSS SLPGLGLEQD RQGPEESDEF QS
//
